- Home
- EVOK vs GLTO Comparison
EVOK vs GLTO Comparison
Compare EVOK & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- GLTO
- Stock Information
- Founded
- EVOK 2007
- GLTO 2011
- Country
- EVOK United States
- GLTO Denmark
- Employees
- EVOK N/A
- GLTO N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- GLTO Health Care
- Exchange
- EVOK Nasdaq
- GLTO Nasdaq
- Market Cap
- EVOK 6.5M
- GLTO 6.5M
- IPO Year
- EVOK 2013
- GLTO 2020
- Fundamental
- Price
- EVOK $4.47
- GLTO $5.30
- Analyst Decision
- EVOK
- GLTO Buy
- Analyst Count
- EVOK 0
- GLTO 1
- Target Price
- EVOK N/A
- GLTO $10.00
- AVG Volume (30 Days)
- EVOK 29.5K
- GLTO 21.2K
- Earning Date
- EVOK 03-13-2025
- GLTO 03-07-2025
- Dividend Yield
- EVOK N/A
- GLTO N/A
- EPS Growth
- EVOK N/A
- GLTO N/A
- EPS
- EVOK N/A
- GLTO N/A
- Revenue
- EVOK $8,617,036.00
- GLTO N/A
- Revenue This Year
- EVOK $97.35
- GLTO N/A
- Revenue Next Year
- EVOK $99.52
- GLTO N/A
- P/E Ratio
- EVOK N/A
- GLTO N/A
- Revenue Growth
- EVOK 100.35
- GLTO N/A
- 52 Week Low
- EVOK $3.54
- GLTO $4.40
- 52 Week High
- EVOK $12.32
- GLTO $23.50
- Technical
- Relative Strength Index (RSI)
- EVOK 47.52
- GLTO 52.98
- Support Level
- EVOK $4.30
- GLTO $4.60
- Resistance Level
- EVOK $4.58
- GLTO $5.85
- Average True Range (ATR)
- EVOK 0.26
- GLTO 0.41
- MACD
- EVOK -0.00
- GLTO 0.09
- Stochastic Oscillator
- EVOK 48.22
- GLTO 65.21
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.